Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Andrea Mahr, Jens Fritsche, Phillip Mueller, Anita Wiebe, Sarah Kutscher
Life of this patent
Estimating the term…
Abstract
A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
Claims19
A peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO:
- 56) in the form of a pharmaceutically acceptable salt.
A pegylated peptide consisting of the amino acid sequence of GVLPGLVGV (SEQ ID NO:
- 56) or a pharmaceutically acceptable salt thereof, wherein a polyethylene glycol (PEG) is cross-linked to the amino acid sequence.
Dependencies are inferred from the claim text.